Bitcoin price today: slips below $113k, near 6-wk low despite Fed cut bets
Investing.com - Roth/MKM has raised its price target on SANUWAVE Health (NASDAQ:SNWV) to $54.00 from $49.00 while maintaining a Buy rating following the company’s second-quarter 2025 results. The stock has shown remarkable momentum, delivering a 554% return over the past year and currently trading near its 52-week high of $41.68.
The company’s Q2 performance aligned with its preliminary sales announcement but significantly exceeded analyst expectations for AEBITDA margin, which came in at 33% compared to the 23% forecast by Roth/MKM and Wall Street. According to InvestingPro data, SANUWAVE has achieved impressive revenue growth of 57.42% with a robust gross margin of 77.69%.
SANUWAVE Health has completed building out its commercial team and is on track to finish updating the manufacturing process for its applicator in the fourth quarter of 2025, according to Roth/MKM’s analysis.
The research firm noted favorable adoption and awareness of the company’s UltraMIST product within the provider community, which is expected to support continued strong sales growth and earnings leverage.
Roth/MKM cited the company’s margin outperformance, resulting higher forward estimates, and impressive financial position compared to peers as key factors behind the price target increase.
In other recent news, SANUWAVE Health Inc. has reported impressive financial results for the second quarter of 2025. The company achieved a significant 42% increase in revenue compared to the same period last year. This notable growth highlights SANUWAVE’s strategic initiatives in expanding its market presence and focusing on product innovation. The positive financial performance was well-received by investors, as reflected in the market’s reaction. Although the company’s stock price movement is not detailed here, the revenue increase is a key highlight. These developments underscore SANUWAVE’s ongoing efforts to strengthen its position in the industry. The company’s recent activities and financial outcomes are pivotal for investors to consider.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.